Salivary secretory leukocyte protease inhibitor increases in HIV infection

Journal of Oral Pathology and Medicine

Volumn 33, Issue 7, 2004, Pages 410-416

  Lin, Alan L ^a   Johnson, Dorthea A ^a   Stephan, Kevin T ^b   Yeh, Chih Ko ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

HAART; HIV; Saliva; SLPI

Indexed keywords

ANTIRETROVIRUS AGENT; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ADULT; ANTIGEN DETECTION; ANTIMICROBIAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; FLOW RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PAROTID GLAND; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEINASE INHIBITION; SALIVA ANALYSIS; SALIVARY GLAND FUNCTION; SUBLINGUAL GLAND; SUBMANDIBULAR GLAND;

ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HUMANS; MALE; PROTEIN BIOSYNTHESIS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; SALIVA; SALIVARY GLANDS; SALIVARY PROTEINS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SECRETORY RATE; STATISTICS, NONPARAMETRIC; VIRAL LOAD;

EID: 3343007202     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2004.00218.x     Document Type: Article

References (43)

1. Rothenberg RB, Scarlett M, del Rio C, Reznik D, O'Daniels C. Oral transmission of HIV. AIDS 1998; 12: 2095-105.
2. Scully C, Porter S. HIV topic update: oro-genital transmission of HIV. Oral Dis 2000; 6: 92-8.
3. Barr CE, Miller LK, Lopez MR, et al. Recovery of infectious HIV-1 from whole saliva. J Am Dent Assoc 1992; 123: 37-48.
4. Coppenhaver DH, Sriyuktasuth-Woo P, Baron S, Barr CE, Qureshi MN. Correlation of nonspecific antiviral activity with the ability to isolate infectious HIV-1 from saliva. N Engl J Med 1994; 330: 1314-5.
5. Fultz PN. Components of saliva inactivate human immunodeficiency virus. Lancet 1986; 2 (8517): 1215.
6. Fox PC, Wolff A, Yeh CK, Atkinson JC, Baum BJ. Saliva inhibits HIV-1 infectivity. J Am Dent Assoc 1988; 116: 635-7.
7. Shugars DC. Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis 1999; 179 (Suppl. 3): S431-S435.
8. Shugars DC, Alexander AL, Fu K, Freel SA. Endogenous salivary inhibitors of human immunodeficiency virus. Arch Oral Biol 1999; 44: 445-53.
9. Shugars DC, Wahl SM. The role of the oral environment in HIV-1 transmission. J Am Dent Assoc 1998; 129: 851-8.
10. Nagashunmugam T, Friedman HM, Davis C, Kennedy S, Goldstein LT, Malamud D. Human submandibular saliva specifically inhibits HIV type 1. AIDS Res Hum Retroviruses 1997; 13: 371-6.
11. Franken C, Meijer CJ, Dijkman JH. Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem 1989; 37: 493-8.
12. Ohlsson M, Fryksmark U, Polling A, Tegner H, Ohlsson K. Localization of antileukoprotease in the parotid and the submandibular salivary glands. Acta Oto-Laryngol 1984; 98: 147-51.
13. Tomee JF, Hiemstra PS, Heinzel-Wieland R, Kauffman HF. Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. J Infect Dis 1997; 176: 740-7.
14. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996; 64: 4520-4.
15. Kido H, Beppu Y, Imamura Y, et al. The human mucus protease inhibitor and its mutants are novel defensive compounds against infection with influenza A and Sendai viruses. Biopolymers 1999; 51: 79-86.
16. Ashcroft GS, Lei K, Jin W, et al. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 2000; 6: 1147-53.
17. Westin U, Fryksmark U, Polling A, Ohlsson K. Localisation of secretory leucocyte proteinase inhibitor mRNA in nasal mucosa. Acta Oto-Laryngol 1994; 114: 199-202.
18. Casslen B, Rosengren M, Ohlsson K. Localization and quantitation of a low molecular weight proteinase inhibitor, antileukoprotease, in the human uterus. Hoppe-Seylers Zeitschrift fur Physiologische Chemie 1981; 362: 953-61.
19. Dijkman JH, Kramps JA, Franken C. Antileukoprotease in sputum during bronchial infections. Chest 1986; 89: 731-6.
20. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96: 456-64.
21. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90: 1141-9.
22. Hocini H, Becquart P, Bouhlal H, Adle-Biassette H, Kazatchkine MD, Belec L. Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin Diagn Lab Immunol 2000; 7: 515-8.
23. Wahl SM, Worley P, Jin W, et al. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues. Am J Pathol 1997; 150: 1275-84.
24. Baqui AA, Meiller TF, Falkler WA. Jr Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol 1999; 6: 808-11.
25. Dupont B, Crewe Brown HH, Westermann K, et al. Mycoses in AIDS. Med Mycol 2000; 38 (Suppl. 1): 259-67.
26. Blatt SP, McCarthy WF, Bucko-Krasnicka B, et al. Multivariate models for predicting progression to AIDS and survival in human immunodeficiency virus-infected persons. J Infect Dis 1995; 171: 837-44.
27. Yeh CK, Fox PC, Ship JA, et al. Oral defense mechanisms are impaired early in HIV-1 infected patients. J Acquir Immune Defic Syndr 1988; 1: 361-6.
28. Fox PC. Saliva composition and its importance in dental health. Compend Suppl 1989; 13: S457-60.
29. Shannon IL, Suddick RP, Dowd FJ. Jr Saliva: composition and secretion. Monogr Oral Sci 1974; 2: 1-103.
30. Arneberg P. Quantitative determination of protein in saliva. A comparison of analytical methods. Scand J Dent Res 1971; 79: 60-4.
31. Lin AL, Johnson DA, Stephan KT, Yeh C.-K. Alteration in salivary function in early HIV infection. J Dent Res 2003; 82: 719-24.
32. Fryksmark U, Jannert M, Ohlsson K, Tegner H, Wihl JA. Secretory leukocyte protease inhibitor in normal, allergic and virus induced nasal secretions. Rhinology 1989; 27: 97-103.
33. Vogelmeier C, Hubbard RC, Fells GA, et al. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 1991; 87: 482-8.
34. Itescu S, Brancato LJ, Buxbaum J, et al. A diffuse infiltra live CD8 lymphocytosis syndrome in human immunodeficiency virus (HIV) infection: a host immune response associated with HLA-DR5. Ann Intern Med 1990; 112: 3-10.
35. Trudgill NJ, Smith LF, Kershaw J, Riley SA. Impact of smoking cessation on salivary function in healthy volunteers. Scand J Gastroenterol 1998; 33: 568-71.
36. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280: 1497-503.
37. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 1998; 280: 72-7.
38. Carr A, Cooper DA. HIV protease inhibitors. AIDS 1996; 10(Suppl. A): 151-7.
39. Cassone A, De Bernardis F, Mondello F, Ceddia T, Agatensi L. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 1987; 156: 777-83.
40. De Bernardis F, Arancia S, Morelli L, et al. Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 1999; 179: 201-8.
41. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-92.
42. Hube B. Candida albicans secreted aspartyl proteinases. Curr Top Med Mycol 1996; 7: 55-69.
43. Sreebny LM. Salivary flow in health and disease. Campend Suppl 1989; 13: S461-9.